JP Morgan Chase
XRTX

JP Morgan Chase’s XORTX Therapeutics XRTX Stock Holding History

JP Morgan Chase’s Portfolio XRTX Stock Details XRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-51
Closed -$1.21K – 7770
2024
Q3 		$1.21K Hold
51
– – ﹤0.01% 6697
2024
Q2 		$1.21K Hold
51
– – ﹤0.01% 6586
2024
Q1 		$1.21K Buy
+51
New +$799 ﹤0.01% 6629

Other funds holding XRTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

JP Morgan Chase's XRTX Position: Q4 2024 in Review

JP Morgan Chase sold out of XORTX Therapeutics (XRTX) in Q4 2024, closing a stake of 51 shares — an estimated $1.21K sold.

JP Morgan Chase first reported a position in XRTX in Q1 2024 and held it in 3 quarters. The position peaked at $1.21K in Q3 2024. 6 funds tracked by Wall St. Rank hold XRTX as of Q4 2024.

  • JP Morgan Chase reported no remaining XORTX Therapeutics position as of Q4 2024 after selling out during the quarter.
  • JP Morgan Chase sold 51 XORTX Therapeutics shares in Q4 2024, an estimated $1.21K.
  • JP Morgan Chase first reported a position in XORTX Therapeutics in Q1 2024 and held it in 3 quarters.
  • JP Morgan Chase's XORTX Therapeutics position peaked at $1.21K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.